Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C

Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C

Background: An estimated 170 million individuals worldwide are infected with the hepatitis C virus (HCV). Although treatment options using a combination of pegylated interferon and ribavirin (P-IFN/RBV) are available, sustained clearance of the virus is only achieved in approximately 40% of individu...

Full description

Bibliographic Details
Main Authors: Dorta Guridi Zaily, MD, PhD, MS, PM, Castellanos Fernandez Marlen, MD, PhD, MS, PM, Dueñas-Carrera Santiago, PhD, Martínez Donato Gillian, PhD, MS, Valenzuela Silva Carmen, MS, Cinza Estevez Zurina, MD, MS, Arús Soler Enrique R., MD, PhD, PM, Alvarez-Lajonchere Liz, PhD, González Fabián Lisset, MD, MS, Lazo del Vallín Sacha, MD, MS, Ferrer Bataille Elena, LIC
Format: Article
Language:English
Published: Elsevier 2017-01-01
Series:Current Therapeutic Research
Subjects:
Hepatitis C
Therapeutic vaccine
Online Access:http://www.sciencedirect.com/science/article/pii/S0011393X16300923

Internet

http://www.sciencedirect.com/science/article/pii/S0011393X16300923

Similar Items